Winslow G A, Nelson E W
Department of Surgery, University of Utah Health Sciences Center, Salt Lake City 84132, USA.
Am J Surg. 1995 Dec;170(6):558-61; discussion 561-3. doi: 10.1016/s0002-9610(99)80015-4.
Thrombotic thrombocytopenic purpura (TTP) is a rare, life-threatening disorder of unknown pathophysiology. The role of splenectomy in the multimodality therapy of TTP is controversial.
All charts of patients with TTP at the University of Utah between 1984 and 1994 were reviewed to evaluate various treatment regimens, and specifically, the impact of splenectomy on morbidity and survival.
Of the 15 patients identified, 14 underwent initial treatment with plasmapheresis and steroids. Nine patients were treated with medical therapy only, 6 of whom completely recovered, while 3 patients died. Six patients failed plasmapheresis and underwent splenectomy. There were no operative complications or postoperative deaths. All surgical patients had no active disease at last follow-up.
Plasmapheresis and steroid administration remain the first-line therapy for TTP. This series documents that splenectomy offers excellent results with minimal morbidity and mortality in patients who do not respond to or who relapse after plasmapheresis.
血栓性血小板减少性紫癜(TTP)是一种病因不明、罕见且危及生命的疾病。脾切除术在TTP多模式治疗中的作用存在争议。
回顾了1984年至1994年间犹他大学所有TTP患者的病历,以评估各种治疗方案,特别是脾切除术对发病率和生存率的影响。
在确定的15例患者中,14例接受了血浆置换和类固醇的初始治疗。9例患者仅接受药物治疗,其中6例完全康复,3例死亡。6例血浆置换治疗失败的患者接受了脾切除术。无手术并发症或术后死亡。所有手术患者在最后一次随访时均无活动性疾病。
血浆置换和类固醇给药仍然是TTP的一线治疗方法。本系列资料表明,对于血浆置换无反应或复发的患者,脾切除术疗效极佳,发病率和死亡率极低。